

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
				33,484-00
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/019164</b>
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE		PRIORITY DATE CLAIMED	
PCT/US00/17020	June 20, 2000		June 25, 1999	
TITLE OF INVENTION		Production of the Lipidated Form of the Peptidoglycan-Associated Lipoproteins of Gram-Negative Bacteria		
APPLICANT(S) FOR DO/EO/US <u>Benjamin J. Metcalf</u>				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). (copy of Abstract page 41 is enclosed)</li> </ul> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ul> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ul> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
Items 11 to 20 below concern document(s) or information included:				
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p> <p>a) Rule 821 (f) Statement b) International Search Report c) International Preliminary Examination Report</p>				
CERTIFICATE OF MAILING 37 CFR §1.10				
<p>I hereby certify that this paper and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET937267987US addressed to the Commissioner for Patents, Washington, DC 20231.</p> <p><u>12/20/01</u></p> <p>Date</p> <p><u>Alan M. Gordon</u></p> <p>Alan M. Gordon</p>				

U.S. APPLICATION NO. (If known, see 37 CFR 1.16) <b>10/019164</b>		INTERNATIONAL APPLICATION NO. PCT/US00/17020	ATTORNEY'S DOCKET NUMBER 33,484-00
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
<b>BASIC NATIONAL FEE</b> (37 CFR 1.492 (a) (1) - (5)):			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. ....		\$1040.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....		\$890.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....		\$740.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....		\$710.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....		\$100.00	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$ 890.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	17 - 20 =	0	x \$18.00
Independent claims	5 - 3 =	2	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$ 1,058.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+	
<b>SUBTOTAL =</b>		\$ 1,058.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
<b>TOTAL NATIONAL FEE =</b>		\$ 1,058.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$	
<b>TOTAL FEES ENCLOSED =</b>		\$ 1,058.00	
		Amount to be refunded:	\$
		charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>01-1300</u> in the amount of \$<u>1,058.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>01-1300</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>			
<p><b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p>			
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Alan M. Gordon American Home Products Corp. Patent Law Department Five Giralda Farms Madison, NJ 07940 (845) 602-4636</p>			
<p><u>Alan M. Gordon</u> SIGNATURE</p> <p>Alan M. Gordon NAME</p> <p>30,637 REGISTRATION NUMBER</p>			

33,484-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Benjamin J. Metcalf  
Serial No. : To be Assigned (Entry into National Stage  
from PCT/US00/17020)  
Filed : December 20, 2001  
For : Production of the Lipidated Form of the  
Peptidoglycan-Associated Lipoprotein of  
Gram-Negative Bacteria  
Examiner : To be Assigned  
Group Art Unit : To be Assigned  
Confirmation No.: To be Assigned Customer No.: 25291

December 20, 2001

BOX PATENT APPLICATION  
Hon. Commissioner for Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. 1.821(f)

Sir:

I hereby certify that the content of the paper  
copy required by 37 C.F.R. 1.821(c) and the computer  
readable form required by 37 C.F.R. 1.821(e) of the Sequence

-----  
CERTIFICATION UNDER 37 C.F.R. 1.10

I hereby certify that this paper and the documents referred to as  
enclosed therein are being deposited with the United States Postal Service on  
the date written below in an envelope as "Express Mail Post Office to Addressee"  
Mailing Label Number ET937267987US addressed to the Commissioner for Patents,  
Washington, D.C. 20231.

12/20/01

Date

Alan M. Gordon

Alan M. Gordon

Listings for the above-captioned U.S. national stage application based on PCT international patent application number PCT/US00/17020 as filed are the same, that is, the information recorded in computer readable form is identical to the written Sequence Listing, and the submission contains no new matter.

Respectfully submitted,

  
Alan M. Gordon  
Registration No. 30,637  
American Home Products Corp.  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
(845) 602-4636  
Attorney for Applicant

L:\amend1ag\1agrj29.doc

13022007-162900

10/019164

SEQUENCE LISTING

531 Rec'd PCT/PTC 20 DEC 2001

<110> American Cyanamid Company

<120> PRODUCTION OF THE LIPIDATED FORM OF THE  
PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEINS OF GRAM-NEGATIVE  
BACTERIA

<130> 33484-00PCT

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 24

<212> DNA

<213> Haemophilus influenzae

<400> 1

ggagaaaatca tatgaacaaa ttgg

24

<210> 2

<211> 32

<212> DNA

<213> Haemophilus influenzae

<400> 2

ggatcctgtt tttcaaggctt agaaaatacta ag

32

Sequence Listing

10/019164

531 Rec'd PCT/FT 20 DEC 2001

33,484-00PCT

- 41 -

Abstract of the Disclosure

The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that the lipidated recombinant PAL is expressed. The lipidated recombinant PAL is included in an antigenic composition administered to a mammalian host to immunize against a gram-negative bacterium.

10019164 20 DEC 2001

WO 01/00790

10/019164  
PCT/US00/17020PRODUCTION OF THE LIPIDATED FORM OF THE PEPTIDOGLYCAN-  
ASSOCIATED LIPOPROTEINS OF GRAM-NEGATIVE BACTERIAField Of The Invention

5

This invention is directed to the expression of the lipidated form of the peptidoglycan-associated protein of gram-negative bacteria and the use of that recombinant lipidated protein in antigenic compositions.

Background Of The Invention

The cell walls of gram-negative bacteria contain cross-linked moieties known as peptidoglycans. A number of gram-negative bacteria produce proteins which are covalently linked to the peptidoglycans. Such a protein is referred to as a peptidoglycan-associated lipoprotein (PAL). PALs are present as part of the tol locus in a number of gram-negative bacteria, including *Legionella pneumophila* (Bibliography entry 1), *Escherichia coli* (2), *Haemophilus ducreyi* (3), *Campylobacter jejuni* (4), *Pseudomonas putida* (5), *Brucella abortus* (6), *Pseudomonas aeruginosa*, *Klebsiella aerogenes*, *Serratia marcescens*, *Proteus vulgaris*, *Salmonella typhimurium* (7) *Actinobacillus pleuropneumoniae* (8), *Helicobacter pylori* (9) *Chlamydia pneumoniae* (10), and *Chlamydia trachomatis* (11).

25

Other PAL-containing bacteria are the *Haemophilus influenzae* (*H. influenzae*) bacteria. The *H. influenzae* bacteria are divided into two groups. Those strains which possess a known capsule are typed by the serological reaction of the capsule with reference antisera. Types a-f have been identified. Strains which fail to react with any of the reference

- 2 -

antisera are known as nontypable.

5 *H. influenzae* type b (Hib) is the most frequent cause of neonatal meningitis and other invasive infections in the United States (12). The major incidence of childhood meningitis occurs between the ages of one and five years. Sixty percent of those meningitis cases due to Hib occur in children under the age of two (12).

10 Nontypable *H. influenzae* (NTHi) is a gram-negative organism which causes a number of diseases, including pneumonia, bacteremia, meningitis, postpartum sepsis, and acute febrile tracheobronchitis in adults (13). NTHi has been reported to cause between 20 and 40 percent of all cases of otitis media seen in young children (14,15,16). Children may experience multiple infections due to the same organism since infection confers no long lasting immunity. Current therapy for chronic or repeated occurrences of otitis media includes administration of antibiotics and insertion of tubes to drain the inner ear. NTHi strains have also been implicated as a primary cause of sinusitis (17). Additionally, NTHi causes neonatal sepsis.

25 Current capsular-based antigenic compositions are ineffective against NTHi. The surface of these bacteria has been shown to be extremely antigenically variable, with the major outer membrane proteins, P1 and P2, being particularly diverse (18,19). In humans, the presence of serum bactericidal antibodies has been reported to correlate with protection from otitis media caused by sensitive NTHi strains (20).

30 35 Candidates for inclusion in antigenic compositions against NTHi should be highly conserved at the amino acid level, surface exposed (in particular, outer membrane proteins), elicit bactericidal antibodies, and be present in all isolates. Previous

research has shown that the P6 (also known as PBOMP-1 and HiPAL) (21) protein of NTHi meets all of these criteria. The purified native proteins have been shown to elicit bactericidal antibodies (22,23,24,25) and are conserved antigenically (22,23,26,27).

Evaluation of the genetic sequence of the P6 gene has shown that it is highly conserved among otic NTHi isolates and thus the protein sequence is also highly conserved. Native P6 is a lipoprotein, more specifically a PAL, which is modified at the amino-terminal cysteine with lipids. This protein is present in *H. influenzae* in relatively small amounts (less than 1% of total outer membrane proteins), making purification from the native organism of useful quantities quite difficult. Thus, a recombinant version of P6 is required for further development as a component in antigenic compositions.

Several laboratories were unable to express lipidated rP6 in large quantities in *E. coli* (28,29). As a result, initial recombinant constructs expressing P6 in *E. coli* could express only a nonlipidated version of the protein. These groups reported that, while the lipidated P6 protein purified from *H. influenzae* was more immunogenic than nonlipidated rP6 purified from *E. coli*, it was difficult to engineer a DNA vector which would express lipidated P6 (28,29); i.e., not better than the low levels of native P6 expressed by *H. influenzae*.

Previous attempts to express lipidated rP6 relied on promoters which were not under tight transcriptional regulation, such as trc, taq, lac and  $P_{L}-C1857$ . It was theorized that this somewhat leaky transcription led to subtle effects on the *E. coli* which contributed to low levels of expression of the lipidated protein. Experimental evidence indicated

- 4 -

that the ability of signal peptidase II to add lipid to the N-terminus of the protein was not responsible for the low yield of processed P6 (data not shown).

While the P6 protein of *H. influenzae* has been a primary candidate for inclusion in antigenic compositions against *Haemophilus* disease (20,23,24,25,30,31), the relatively small amounts available from *H. influenzae* have made recombinant expression of this protein essential. Previous efforts to express lipidated P6 protein in meaningful quantities have been unsuccessful (28,29). Thus, researchers have focused on the expression and purification of multiple forms of nonlipidated P6.

The antibody response engendered by the nonlipidated rP6 was biologically functional, capable of protecting infant rats from meningitis (28) and eliciting bactericidal antibodies (28,29), but of a lower magnitude than those elicited by lipidated native P6 (28).

Therefore, there is a need to construct host cell-expression vector systems which express lipidated PALs of gram-negative bacteria. In particular, there is a need to construct host-cell expression vector systems which express lipidated rP6, which can then be included in antigenic compositions against *H. influenzae*.

#### Summary Of The Invention

Thus, it is an object of this invention to develop genetic constructs capable of expressing lipidated PALs of gram-negative bacteria in bacterial host cells.

It is a particular object of this invention to develop genetic constructs capable of expressing

- 5 -

lipidated rP6 in bacterial host cells, in particular, in *E. coli*.

It is a further object of this invention to include that lipidated rP6 in antigenic compositions for administration to a mammal to prevent disease caused by *H. influenzae*.

These and other objects of the invention as discussed below are achieved by the cloning and expression in bacterial cells of the lipidated forms of P6s through the use of tightly regulated promoters in the expression vectors.

The invention is exemplified by the cloning and expression in bacterial cells of the lipidated form of recombinant *H. influenzae* P6 protein through the use of such promoters in the expression vector.

Specifically, for the expression of lipidated recombinant P6, plasmids are constructed which contain an arabinose inducible promoter or a T7 promoter, wherein the promoter is operatively linked to an isolated and purified DNA sequence comprising a DNA sequence which encodes the P6 protein, and wherein the DNA sequence, under the control of said promoter, is expressed in lipidated form.

In turn, a bacterial host cell is transformed, transduced or transfected with such a plasmid and is then cultured under conditions which permit the expression of the lipidated rP6 by the host cell.

In another embodiment of this invention, the lipidated rP6 is used as an immunogen in antigenic compositions against all pathogenic *H. influenzae*, including both type b and nontypable *H. influenzae*.

When purified, the recombinant protein is indicated to be lipidated by several criteria and, most importantly, is much more immunogenic than the non-

- 6 -

lipidated form of P6 previously used.

The lipid modification of the amino-terminal cysteine by signal peptidase II has been shown to make proteins more immunogenic than their non-lipidated forms (28,29,32). These forms have been evaluated for immunogenicity and antigenic relatedness to lipidated P6. All have shown decreased immunogenicity as compared to the native lipidated protein.

This allows much lower doses to be used to immunize humans and thus makes the lipidated rP6 a more commercially viable candidate for inclusion in antigenic compositions. These increased titers allow the use of lower P6 protein doses in humans, which would provide a cost savings in the production of that protein.

The isolated and purified lipidated rP6 protein is used to prepare an antigenic composition which elicits a protective immune response in a mammalian host. The antigenic composition may further comprise one or more of an adjuvant, diluent or carrier. Examples of such adjuvants include aluminum hydroxide, aluminum phosphate, Stimulon™ QS-21, MPL™, IL-12 and cholera toxin. The antigenic composition is administered to a mammalian host in an immunogenic amount sufficient to protect the host against disease caused by *H. influenzae*.

#### Brief Description Of the Figures

Figure 1 depicts the cloning of the *pal* gene encoding the P6 protein with the native lipoprotein signal peptide by PCR amplification from the chromosome of nontypable *H. influenzae* strain P860295.

Figure 2 depicts the homogeneity and identity of lipidated rP6. Fifteen percent SDS-PAGE gels were

- 7 -

loaded with samples containing approximately 10 $\mu$ g of lipidated rP6 in the initial extract (lane 1) and the pool of anion exchange purified lipidated rP6 (lane 2). Lanes labeled S contain prestained low molecular weight standards from Bio-Rad. Figure 2A is the Coomassie stained gel. Figure 2B is the western immunoblot of a similar gel.

Figure 3 depicts the SDS-PAGE analysis of fractions from the purification of lipidated rP6. Aliquots of steps in the purification process of lipidated rP6 were electrophoresed on a 4-20% gradient gel system. Lanes: 1, Permeate from diafiltration with lysis buffer; 2, Permeate from diafiltration with Triton™ X-100; 3, Permeate from diafiltration with Tris™ buffer; 4, Permeate from diafiltration with Zwittergent™ 3-14; 5, Permeate from diafiltration with Zwittergent™ 3-14/0.5 M NaCl; 6, Permeate from diafiltration with Tris™ buffer; 7, Permeate from diafiltration with sarcosyl; 8, Mark 12 Standard; 9, Permeate from diafiltration with Tris™ buffer; 10, Permeate from diafiltration with Zwittergent™ 3-12 at room temperature; 11, Permeate from diafiltration with Tris™ buffer; 12, Permeate from concentration step; 13, Permeate from diafiltration with Zwittergent™ 3-12 at 55°C; 14, Permeate from diafiltration with Tris™ buffer at 55°C; 15, Permeate from diafiltration with Zwittergent™ 3-12 at 55°C.

#### Detailed Description Of The Invention

In order to overcome the recognized difficulty in expressing usable amounts of lipidated PALs, such as lipidated rP6, a strategy was devised involving the use of tightly regulated promoters and

host strains devoid of cytoplasmic and perplasmic proteases.

5 Previous unsuccessful efforts to express lipidated P6 protein in meaningful quantities for commercial use all relied on changing the promoter sequence and/or making changes in the signal sequence recognized by signal peptidase II.

10 As discussed below, plasmids were constructed containing the pal gene encoding P6 under the control of the T7 promoter (plasmid pPX4019 - Example 1) and the arabinose inducible promoter (plasmid pPX4020 - Example 2). Exemplary bacterial strains and media are described in Example 3. Both pPX4019 and pPX4020 express lipidated P6 protein in the *E. coli* strains tested, as determined by western blot analysis with P6-specific monoclonal antibodies, sizing on SDS-PAGE gels which indicated a lack of a signal sequence and visual observation of expression levels in Coomassie stained gels (see Example 4 and Figures).

15 Plasmid pPX4020 produced increased levels of rP6 protein expression in the *E. coli* strains BL21 and BLR, with the highest levels in strain BLR. Therefore, plasmid pPX4020 was chosen for further studies. Growth of larger quantities of lipidated rP6 expressing *E. coli* was performed in host strain BLR. All subsequent experiments utilized this host-vector system.

20 The plasmid construct described herein as a preferred embodiment (pPX4020) uses the arabinose inducible promoter system which has several unique features: It is tightly regulated and almost completely inactive if no arabinose is present and some glucose is present. It is also modulatable in that it shows increasing induction levels as increasing arabinose is added to the culture medium. These 25 factors in combination with the BLR strain of *E. coli*,

- 9 -

which is highly protease deficient and recombination deficient, allow significant expression of the lipidated P6 protein.

5 Batch scale purification of lipidated rP6 involves differential centrifugation, differential detergent extraction and anion exchange chromatography (see Example 4).

10 However, to become a viable candidate for inclusion in an antigenic composition, the expressed lipidated rP6 must be purified by a method which is amenable to large scale. Diafiltration is a method suitable to large scale purification. The diafiltration process for extracting lipidated rP6 is complicated because lipidated rP6 is tightly associated with peptidoglycans.

15 As described in Example 5, solubilization of the lipidated rP6 was accomplished following differential detergent extraction much like the native protein obtained from *Haemophilus* (Hi-P6) (33), but with tangential flow diafiltration used instead of centrifugation. Detergents such as dodecylmaltoside, deoxycholate, Zwittergent™ 3-08, 3-12, and 3-14 were all tested and found to be acceptable to extract the lipidated rP6 when used in the 0.2-1%(w/v) range. The lipidated rP6 could also be solubilized in a sodium borate buffer, pH 9.5 at 65°C. The flexibility of detergent choice permitted the use of Zwittergent™ 3-12 to extract the lipidated rP6. The choice of Zwittergent™ 3-12 thus minimizes the number of components required to produce a multi-component antigenic composition. Whereas the native Hi P6 is obtained in essentially pure form following solubilization, the recombinant protein is solubilized along with several *E. coli* proteins. The relative amount of these proteins can be varied and in some

20

25

30

35

- 10 -

cases nearly eliminated by the choice of detergent used in the final extract. The lipidated rP6 is separated from any remaining *E. coli* proteins by anion exchange chromatography (see Example 6).

5 This method of extracting PALs combines the clarification and extraction processes into one unit operation. The product is extracted from the cells and it is separated from cell debris with only one continuous diafiltration process. In addition, the PALs are extracted in a semi-purified state which simplifies the downstream processing steps. Finally, this process is very scalable, because the only requirement is that the surface area of the membranes be increased proportionally with the amount of cells. This extraction process avoids the use of centrifugation, a method which is not preferred for use in large scale extraction. After extraction, the lipidated rP6 is purified by conventional techniques.

10 Analysis of the lipidated rP6 was consistent with the characterization of the recombinant protein as a lipoprotein, as expected. The molecular size as determined by MALDI-TOF mass spectrometry shows that the purified recombinant protein is larger than expected from its amino acid sequence alone (see Example 7). The size of the protein, combined with the amino acid analysis detailed in Table 1 (see Example 8), indicate that the signal sequence has been removed and the protein is in the mature form. The existence of a blocked amino-terminus, as demonstrated by amino-terminal amino acid analysis (see Example 9), also shows that modification of the terminal cysteine residue has taken place. Taken together, these results show that the signal sequence, which has been shown to be recognized and processed by *E. coli* resulting in lipidated P6 (23), has been removed and that the

15  
20  
25  
30  
35

- 11 -

recombinant P6 purified here is lipidated at its amino-terminus.

Previous investigators have demonstrated that antibody levels against P6 after naturally occurring NTHi infections have an inverse correlation with disease incidence (34,35,36), making the production of high titers against P6 a goal of any immunization program using this antigen. The native lipidated P6 protein is present in very small quantities (less than 1% of the outer membrane proteins) (33), which makes purification of commercially viable quantities problematic at best.

A critical advantage of the lipid-modified rP6 over the previously expressed non-lipidated rP6 is the enhanced immunogenicity associated with the lipid modification. Two reports have shown that, while non-lipidated rP6 is capable of eliciting biologically active antibodies, it is less immunogenic than the native lipidated protein (28,29).

In contrast, the animal immunogenicity data presented in Tables 2-4 below (see Examples 10 and 11) show that the lipid modification of recombinant P6 also increases the immunogenicity of this antigen in the mouse model. The up to a 2-log increase in geometric mean antibody titers (GMT) at week 6 is quite significant and makes the lipidated form of the rP6 protein a practical candidate for inclusion in antigenic compositions. This is bolstered by the results in these experiments that lipidated rP6 did not interfere with the immune response generated by the other antigens tested.

Taken together, these data support the view that lipidated rP6 is viable for inclusion in antigenic compositions against *H. influenzae*. Although exemplified below with lipidated rP6 from NTHi,

10 C O N F I D E N T I A L  
20

25

30

35

- 12 -

lipidated rP6 from Hib is also suitable for inclusion in the antigenic compositions of this invention.

A variety of bacterial host cell-vector systems are suitable for use to express the lipidated rP6 protein used in the antigenic compositions of this invention in addition to those detailed in Examples 1-3.

These expression systems place the gene encoding the recombinant lipidated PAL under the control of a tightly regulated promoter. Under specific conditions, these promoters operate to down regulate the production of the recombinant PAL mRNA, and consequently mitigate any detrimental effects on the host cell due to the production of the recombinant lipidated PAL (37). This tight regulation can then be removed under specific conditions to allow for maximized recombinant lipidated PAL expression in the host cell.

These tightly regulated promoters (which may be together with other control elements) include, but are not limited to, the arabinose inducible promoter (38), the T7 promoter which may be modified to be under control by nutL/N antitermination function (39,40) or by Mu C (41), the  $P_i$  promoter in combination with antiterminator (42), the SP6 RNA polymerase and SP6 promoters (43), the colicin promoter (44), the tetA promoter/operator (45), the rhamnose and phosphate promoters (46), the LacR/O, tetR/O and AraCII-12 regulatory elements (47), and invertible promoters (48).

The vector system is compatible with the host cell used. Suitable host cells include bacteria transformed, transfected or transduced by conventional techniques with plasmid DNA, cosmid DNA or bacteriophage DNA. Examples of bacterial hosts include

- 13 -

*E. coli, B. subtilis, Salmonella and Shigella.*

To construct such a vector, the pal DNA is inserted into a plasmid vector containing a promoter under tight transcriptional control, and other control elements are ligated into specific sites within the vector, so that when the plasmid vector is inserted into a bacterial host cell, the pal DNA can be expressed by the host cell.

The plasmid is introduced into the host cell by transformation, transduction or transfection, depending on the host cell-vector system used. The host cell is then cultured under conditions which permit expression of the lipidated rP6 protein by the host cell. A host cell containing a plasmid with the arabinose inducible promoter is induced with L-arabinose, while a host cell containing a plasmid with the T7 promoter is induced with IPTG.

The lipidated PALs are useful in the preparation of antigenic compositions to confer protection to mammals against diseases caused by the corresponding bacteria. For example, the lipidated rP6 protein is useful in the preparation of antigenic compositions to confer protection to mammals against diseases caused by *H. influenzae*.

These antigenic compositions comprise an isolated and purified lipidated PALs, such as lipidated rP6 protein, wherein the antigenic composition elicits a protective immune response in a mammalian host. Multivalent antigenic compositions are provided by including other proteins, such as by combining the lipidated rP6 with the UspA2 protein of *Moraxella catarrhalis* (which is described in PCT International Application Number WO 98/28333 (49), which is hereby incorporated by reference), a causative agent of bacterial otitis media, and the recombinant lipidated

10  
15  
20  
25  
30

35

- 14 -

5 rP4 protein of *H. influenzae* (also known as protein "e") (which is described in United States Patent Number 5,601,831 (50), which is hereby incorporated by reference).

10 Antigenic compositions containing a lipidated PAL, such as lipidated rP6 protein, may be mixed with immunologically acceptable diluents or carriers in a conventional manner to prepare injectable liquid solutions or suspensions. Such diluents or carriers include, but are not limited to, PBS, physiologic saline, buffered isotonic solutions, liposomes and ISCOMS. The level of antibodies elicited by the antigenic compositions may be improved by using certain adjuvants such as aluminum hydroxide, aluminum phosphate, Stimulon™ QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, MA), MPL™ (3-O-deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamilton, MT), IL-12 (Genetics Institute, Cambridge, MA), the heat-labile toxin of *E. coli*, and cholera toxin (either in a wild-type or mutant form, for example wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with PCT International Application Number WO 00/18434) (51).

15 The antigenic compositions of this invention are administered by injection in a conventional manner, such as subcutaneous, intradermal or intramuscular injection into humans, as well as by oral, mucosal, intranasal or vaginal administration, to induce an active immune response for protection against disease caused by a gram-negative bacterium, such as *H. influenzae*. The dosage to be administered is determined by means known to those skilled in the art. Protection may be conferred by a single dose of the antigenic compositions, or may require the

- 15 -

administration of several doses, in addition to booster doses at later times to maintain protection.

In order that this invention may be better understood, the following examples are set forth. The examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention.

#### Examples

10 Standard molecular biology techniques are utilized according to the protocols described in Sambrook et al. (52).

##### Example 1

###### Construction of Plasmid pPX4019 Containing the pal Gene and the T7 Promoter

15 As depicted in Figure 1, the *pal* gene encoding the P6 protein was cloned with the native lipoprotein signal peptide by PCR amplification from the chromosome of non-typable *H. influenzae* strain P860295. Using mutagenic primers which created an *Nde*I restriction site encompassing the start codon at the 5' end of the gene (GGAGAAATCATATGAACAAATTG) (SEQ ID NO:1) and a *Hind*III site in the region 3' of the stop codon (GGATCCTGTTTCAAGCTTAGAAATACTAAG) (SEQ ID NO:2), the PCR fragment containing the *pal* gene was cloned into the pCRII expression vector (Invitrogen, Carlsbad, CA) and screened by restriction analysis. The resulting plasmid was used as the source for the *Nde*I/*Hind*III fragment containing the *pal* gene for P6 which was cloned into the *Nde*I and *Hind*III sites of expression vector pET27b (Novagen, Madison, WI). The design of this construction places the gene for P6 under the

25

30

35

- 16 -

control of the T7 promoter and takes advantage of a consensus ribosome binding site in the vector. The initial clones were identified in a non-permissive *E. coli* host (DH5 $\alpha$ ) by restriction analysis. A single plasmid isolate was chosen and saved as pPX4019. This plasmid was used to transform the permissive host strain BL21(DE3,pLysS) (Novagen) for expression studies.

10  
15  
20  
25  
30  
35

Example 2  
Construction of Plasmid pPX4020 Containing the *pal* Gene and the Arabinose Inducible Promoter

A second P6 protein expression plasmid was constructed placing the *pal* gene under the control of the tightly regulated arabinose inducible promoter (38). This plasmid was generated by subcloning the *Xba*I/*Hind*III fragment from the plasmid pPX4019 containing the *pal* gene and the consensus ribosome binding site from pET27b into the similarly digested plasmid pBAD18-Cm (see Figure 1). Clones were screened by restriction analysis followed by expression studies on selected candidates. One of the pBAD18-Cm isolates which expressed P6 protein was designated pPX4020.

25  
30  
35

Example 3  
Expression of Lipidated rP6 from pPX4019 and pPX4020

Qualitative expression studies comparing different isolates, plasmid constructs, *E.coli* host strains and concentration of inducer (IPTG for pPX4019, L-arabinose (Sigma Chemical Co., St. Louis, MO) for pPX4020) were all performed in a similar manner to provide for a consistent background for comparison. Single colony isolates were grown overnight at 37°C in

- 17 -

HySoy™ media, 1% glucose and the appropriate antibiotic for plasmid selection (pPX4019, 15 µg/ml Kanamycin; and pPX4020, 15 µg/ml Chloramphenicol). These cultures were diluted to a OD<sub>600</sub> = 0.5 in HySoy™ 1% glycerol and antibiotic, grown at 37°C to a OD<sub>600</sub> = 2-4 and induced. Samples equivalent to a OD<sub>600</sub> = 1.0 were taken at time points just prior to induction, at two hours and 18 hours post-induction. These samples were centrifuged and the cell pellets resuspended in 150 µl SDS-PAGE loading buffer (ISS, Natick, MA). Comparisons were made from Coomassie blue stained 15% SDS-PAGE gels with 15µl of sample loaded per lane.

E. coli Host Cell Strains Used to Express Lipidated rP6 from Plasmid pPX4019:

DH5α - φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recAlendAl hsdR17(r<sub>k</sub><sup>-</sup>,m<sub>k</sub><sup>+</sup>) phoA supE44λ<sup>-</sup> thi-1 gyrA96 relA1 (Life Technologies, Rockville, MD)

BL21(DE3) - ompT lon hsdS<sub>B</sub> (r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm (DE3) (Novagen)

E. coli Host Cell Strains Used to Express Lipidated rP6 from Plasmid pPX4020:

DH5α - φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recAlendAl hsdR17(r<sub>k</sub><sup>-</sup>,m<sub>k</sub><sup>+</sup>) phoA supE44λ<sup>-</sup> thi-1 gyrA96 relA1 (Life Technologies)

BLR - ompT lon hsdS<sub>B</sub> (r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm Δ(srl-recA)306::Tn10(tet<sup>r</sup>) (Novagen)

BL21(DE3) - ompT lon hsdS<sub>B</sub> (r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm (DE3) (Novagen)

- 18 -

**Growth of *E. coli* BLR(pPX4020) expressing L-rP6:**

Recombinant *E. coli* cells expressing  
 5 lipitated rP6 were grown in a fermenter as described  
 below. Growth media containing the following materials  
 was prepared and sterilized *in situ* for fermenters and  
 by autoclaving for flask growth.

10 **Solution A.**

Material	g/L*
Potassium phosphate, monobasic	3.0
Potassium phosphate, dibasic	7.0
Ammonium sulfate	1.0
Sodium citrate dihydrate	1.0
Ferrous sulfate, heptahydrate	0.09
Glycerol (Remove flask medium before adding)	5 mL/L
Sodium Sulfate	0.58
1000X Trace Mineral Solution (see below)	1 mL/L
Do not pH adjust - Autoclave	

\* unless otherwise stated

1000X Trace Mineral Solution	g/100 mL
Zinc sulfate, heptahydrate	3.0
Cupric sulfate, pentahydrate	0.9
Manganese sulfate, monohydrate	0.42
Cobalt chloride, hexahydrate	0.06
Molybdic acid	0.15

- 19 -

Pre-inoculation Feed Solution: MCG

Ingredient	g/L
Glucose	500
Magnesium sulfate, heptahydrate	11
Calcium chloride	0.83

EDTA Solution

Ingredient	g/L
EDTA	186.15

5  
10 Sterile media containing Solution A and the  
15 Mineral solution was aliquoted into shake flasks and 20  
ml of MCG added per liter of media. Chloramphenicol  
was added to 50  $\mu$ g/ml. The starter cultures were  
incubated with 200-300  $\mu$ l of *E. coli* BLR (pPX4020)  
from a frozen stock. The cells were grown at 30°C with  
aeration for 16 hours. A 10 liter fermenter containing  
growth media, supplemented as above, was inoculated  
with the above culture to an OD<sub>600</sub> of approximately 0.2.

15 Fermenter control parameters were set as  
follows:

Temperature	36°C
pH=	7.0 +/- 0.1
D.O.=	20 to 50% by agitation and pure oxygen
Air and oxygen flow =	20% on rotameter
Antifoam	one drop if necessary
Backpressure	0.5 bar

20 The following solutions were used for control  
of run parameters and were sterilized prior to use:  
PPG-2000-200 mL for foam control if necessary, 40%

- 20 -

ammonium hydroxide-1 L for pH control during growth, 50% glucose-1 L to feed when pH began to rise due to glucose depletion - for continued growth, 4 N acetic acid-500 mL for pH control during induction, 25% arabinose solution, (250g/L) sterile filtered + 1% glycerol - 250 mL (pre-autoclaved). The arabinose/glycerol solution was used to feed after final glucose addition when pH began to rise due to glucose depletion to induce production of protein. The arabinose solution was filter sterilized prior to addition of the autoclaved glycerol stock. The solution was made by adding 100 mL glycerol and 400 mL of 25% arabinose solution for a 10 L fermentation. The final fermenter concentration contained 10 grams/liter arabinose and 10 ml/Liter glycerol.

After inoculation of the fermenter, base (sodium hydroxide) was added as needed for pH control, along with anti-foam (PPG-2000) as needed. Pure oxygen was fed at 800 rpms. When the pH rose above 7.0, 900 mL of 50% glucose was fed to the culture. When the pH was greater than or equal to 7.1, an additional 200 mL of 50% glucose solution was added. These conditions were continued until an OD<sub>600</sub> of approximately 50 was reached.

After an OD<sub>600</sub> of approximately 50 was reached, when the pH rose above 7.0 again, 500 mL of arabinose/glycerol solution was added to induce expression of the LrP6. At this time, acid was used for further pH control. Incubation was continued for three hours post-induction, and then the culture was harvested following addition of 10 mL per liter of 500 mM EDTA solution, pH 8. The culture broth was stored at 4°C until purification of the lipidated rP6.

- 21 -

Example 4

Batch Scale Analytical Purification of Lipidated rP6  
by Differential Detergent Membrane Extraction

5        Batches of the lipidated rP6 expressed from pPX4020 were utilized in subsequent experiments, and were purified by differential detergent membrane extraction as follows:

10        1) Isolation of the *E.coli* membrane fraction: Frozen bacterial cell pellets obtained from fermentation were thawed and suspended in 10 mM HEPES-NaOH, pH 7.4, 1 mM Na<sub>2</sub>EDTA with a volume of buffer equal to five times the weight of the frozen cell pellet. The cell suspension was homogenized in a Microfluidics (Newton, MA) 110-Y microfluidizer to lyse the cells. The membranes were obtained from the cell lysate by differential centrifugation (300,000 x g for 1 hour). The membranes were washed twice with the same volume of the buffer used for lysis, and then frozen as a pellet.

15        2) Solubilization of Lipidated rP6 from *E.coli* membranes: The lipidated P6 was solubilized from *E.coli* using differential detergent extraction similar to that described by Zlotnick et al (33) and Green et al (22). All extractions were carried out for 30 minutes at room temperature unless otherwise stated. All centrifugations were performed using a Beckman 45Ti rotor at 42,000 rpm for one hour with the temperature of the rotor controlled to 10°C unless stated differently. *E. coli* membranes were suspended in 10 mM HEPES-NaOH, pH 7.4, 1mM MgCl<sub>2</sub>, and extracted twice with Triton™ X-100 (Calbiochem-Novabiochem International, San Diego, CA) at a final concentration of 1% (w/v) to remove inner membrane components. The resulting outer membrane pellet was suspended in 50mM Tris™ HCl, pH 8,

25

30

35

- 22 -

5 5mM Na<sub>2</sub>EDTA, which was also used to suspend the subsequent pellets prior to the solubilization of the lipidated rP6. The outer membranes were then sequentially extracted two times with 1% Zwittergent™ 3-14; two times with 1% Zwittergent™ 3-14 and 0.5M NaCl; two times with 1% N-lauryl sarcosine, Na salt; 1% Zwittergent™ 3-14. The final pellet obtained after these extractions was extracted with 0.2% Zwittergent™ 3-12 in 10mM Tris™ HCl, pH 8, 1mM Na<sub>2</sub>EDTA for 45 minutes at 55°C with intermittent mixing followed by centrifugation for at least one hour. The supernatant from this final extraction contained the lipidated rP6.

10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10099 10100 10101 10102 10103 10104 10105 10106 10107 10108 10109 10110 10111 10112 10113 10114 10115 10116 10117 10118 10119 10120 10121 10122 10123 10124 10125 10126 10127 10128 10129 10130 10131 10132 10133 10134 10135 10136 10137 10138 10139 10140 10141 10142 10143 10144 10145 10146 10147 10148 10149 10150 10151 10152 10153 10154 10155 10156 10157 10158 10159 10160 10161 10162 10163 10164 10165 10166 10167 10168 10169 10170 10171 10172 10173 10174 10175 10176 10177 10178 10179 10180 10181 10182 10183 10184 10185 10186 10187 10188 10189 10190 10191 10192 10193 10194 10195 10196 10197 10198 10199 10199 10200 10201 10202 10203 10204 10205 10206 10207 10208 10209 10210 10211 10212 10213 10214 10215 10216 10217 10218 10219 10220 10221 10222 10223 10224 10225 10226 10227 10228 10229 10230 10231 10232 10233 10234 10235 10236 10237 10238 10239 10240 10241 10242 10243 10244 10245 10246 10247 10248 10249 10250 10251 10252 10253 10254 10255 10256 10257 10258 10259 10260 10261 10262 10263 10264 10265 10266 10267 10268 10269 10270 10271 10272 10273 10274 10275 10276 10277 10278 10279 10280 10281

5 densitometer. Laser densitometry of the Coomassie  
stained gel (Figure 2A, lane 2) revealed a single peak  
of greater than 98% homogeneity in the pooled anion  
exchange fractions, indicating that lipidated rP6 had  
been purified to near homogeneity. The identity of  
10 lipidated rP6 in these samples was verified by reacting  
a western blot of the same samples used to determine  
homogeneity with monoclonal antibodies specific for the  
Haemophilus influenzae P6, which do not react to the  
related protein of *E. coli* (data not shown). Results  
15 of the western blot analysis are shown in Figure 2B.  
The lipidated rP6 band was the only band reactive with  
the P6-specific monoclonal antibody in either the crude  
extract (lane 1) or the pooled fractions (lane 2).  
This indicated that the purified protein is, in fact,  
20 P6. No degradation products were observed.

Example 5

Large Scale Purification of Lipidated rP6 Using  
Differential Detergent Membrane Extraction

25 The fermentation broth of *E. coli* cells  
expressing lipidated rP6 was adjusted to 10 mM EDTA and  
diluted to less than or equal to 10% wet weight  
cells/volume prior to homogenization. The cells were  
then lysed with a high-pressure microfluidizer and  
diafiltered at room temperature with a sequence of  
30 buffers using a cross-flow membrane filtration device.  
It was determined that the minimum membrane area to  
allow efficient mass transport of solubilized proteins  
through the membrane was approximately 0.002 m<sup>2</sup>/g wet  
weight cells. The solubilized proteins of approximate  
size less than the 1000 kD molecular weight cut-off  
rating of the membrane passed through with the  
35 permeate, while larger molecules and unsolubilized

- 24 -

proteins were retained. The sequence of diafiltration steps was as follows:

(1) The lysed fermentation broth was diafiltered with 10 mM Hepes/1 mM EDTA/pH 8.0 (lysis buffer) at a volume equal to three times the volume of the retentate to remove intracellular and extracellular contaminants through the permeate.

(2) The lysate was diafiltered three times with 10 mM Hepes/1mM MgCl<sub>2</sub> /0.2% Triton™ X-100 to solubilize and remove inner membrane proteins. The Mg<sup>++</sup> ions stabilized the outer membrane, therefore, the outer membrane proteins were not solubilized in the presence of Triton™ X-100.

(3) The lysate was diafiltered three times with 50 mM Tris™ /5 mM EDTA/0.2% Zwittergent™ 3-14 to solubilize and remove outer membrane proteins (but not lipidated rP6). The EDTA serves to sequester the Mg<sup>++</sup> ions from step (2), as well as to prevent proteolysis.

(4) The lysate was diafiltered three times with 50 mM Tris™/5 mM EDTA/0.5 M NaCl/0.2% Zwittergent™ 3-14 to solubilize and remove additional proteins. NaCl was added to the buffer in this step to disrupt any ionic interactions between membrane proteins and membranes. This step was performed because lipidated rP6 is a PAL, and the salt serves to remove membrane-bound proteins (but not lipidated rP6) from the membrane/outer membrane protein complex. The diafiltration was continued with three retentate volumes of 50 mM Tris™/5mM EDTA to reduce the Zwittergent™ concentration in the retentate.

(5) The lysate was diafiltered three times with 50 mM Tris™ /5 mM EDTA/0.2% sarcosyl to remove additional membrane bound proteins (but not lipidated rP6) and then diafiltered three times with 50 mM Tris™/5 mM EDTA to reduce the sarcosyl concentration in

- 25 -

the retentate.

(6) The lysate was diafiltered three times with 10 mM phosphate/0.2% Zwittergent™ 3-12 to remove additional membrane bound proteins (but not lipidated rP6), and then diafiltered three times with 10 mM sodium phosphate to reduce the Zwittergent™ 3-12 concentration in the retentate.

(7) The lysate was concentrated to 20% of its original volume and then diafiltered three times with 10 mM sodium phosphate/0.2% Zwittergent™ 3-12 at 55°C to solubilize lipidated rP6, which was collected through the permeate. The concentration step was performed prior to diafiltration to increase the concentration of lipidated rP6 in the permeate. The diafiltration was continued for three additional retentate volumes with 10 mM sodium phosphate at 55°C to reduce the Zwittergent™ 3-12 concentration in the retentate. This heating step was performed because (as in step (4) above) lipidated rP6 is a PAL, and heating serves to remove lipidated rP6 from the membrane/membrane protein complex. Finally, the diafiltration was concluded with three retentate volumes of 10 mM sodium phosphate at 55°C.

During the diafiltration steps, the transmembrane pressure was maintained at approximately 10 psi and the cross flow rate was maintained at approximately 120-180 lmh. All the diafiltration processes were run at room temperature, except the final 55°C extraction step, which was run at the higher temperature to solubilize lipidated rP6. The permeate flux ranged from 30 to 50 lmh, which was sufficiently high for the extraction process to be practical and scalable.

During the extraction, samples were taken at various points for analysis by SDS-PAGE to evaluate the

- 26 -

effect of various diafiltration steps on the extraction of proteins. Samples were precipitated by alcohol addition, centrifuged, and then resolubilized at 20% of the original volume in SDS sample prep buffer. This method of preparing samples concentrated the sample and reduced the Triton™ X-100 or Zwittergent™ 3-12 concentration of the samples. Triton™ X-100 or Zwittergent™ 3-12 interfere with the binding of SDS to the sample and reduced the resolution of bands on gels. Ten  $\mu$ l of each sample was loaded on to Novex 10% acrylamide gels and the gels were run for 60-90 minutes at 125 Volts.

A typical SDS-PAGE analysis of the samples taken from the permeate streams during the extraction process of lipidated rP6 is shown in Figures 2 and 3. Lipidated rP6 ran at 15 kilodaltons (kD) on these gels. The gels show that some contaminating proteins were removed during diafiltration with lysis buffer and buffer containing various detergents. There was very little loss of lipidated rP6 during these diafiltration steps. During the final Zwittergent™ 3-12 diafiltration step at 55°C, lipidated rP6 was extracted in a partially purified state. At the end of the second Zwittergent™ 3-12 diafiltration step at 55°C, very little lipidated rP6 was present in the permeate stream. This suggested that most of the solubilized lipidated rP6 had been recovered through the permeate. Other experiments have shown that very little lipidated rP6 remained unsolubilized in the retentate after the completion of the diafiltration process. The 15 kD band of the Zwittergent™ 3-12 / 55°C extract was shown to be lipidated rP6 by western analysis (data not shown).

The use of Zwittergent™ 3-12 in the solubilization of lipidated rP6 resulted in an extract

- 27 -

that contained several proteins in addition to 5  
lipidated rP6. The homogeneity of this extract was  
determined to be approximately 78% lipidated rP6  
(Figure 2, Panel A, lane 1). While this is a high  
degree of homogeneity for an initial solubilization, it  
was desired to separate the LrP6 from these *E. coli*  
proteins if possible. This was carried out as  
described in Example 6.

Example 6

Further Purification Of Purified Lipidated rP6  
by Anion Exchange Chromatography

Anion exchange chromatography was used to 10  
further purify the lipidated rP6 described in Example  
5, because it has been used successfully to purify the  
non-lipidated rP6. The lipidated rP6 adsorbs more  
tightly to the DEAE resin than the rP6, which typically  
elutes with 0.1M NaCl. The lipidated rP6 in 0.2%  
Zwittergent™ required 0.2M NaCl in the buffer before  
desorption occurred. The *E. coli* proteins remained  
adsorbed to the anion exchange resin (DEAE) until after  
the lipidated rP6 was eluted.

The homogeneity and identity of the lipidated 15  
rP6 extracted and purified with 0.2% Zwittergent™ 3-12  
are shown in Figure 2. The homogeneity of the purified  
lipidated rP6 was determined to be greater than 98%  
(Figure 2, Panel A, lane 2).

Example 7

Determination of Molecular Weight by  
MALDI-TOF Mass Spectral Analysis:

Accurate measurement of the molecular weight 20  
of lipidated rP6 expressed from pPX4020 with the

arabinose inducible promoter was carried out by Matrix Assisted Laser Desorption/Ionization Time-of-flight (MALDI-TOF) mass spectrometry using a Finnigan Mat Lasermat™ 2000 linear mass analyzer (Finnigan Mat, Ltd., San Jose, CA). The Lasermat™ uses the technique of matrix-assisted laser desorption (54) to ionize the sample and Time of Flight to analyze the ions produced. The sample was embedded in a matrix of 3,5-dimethoxy-4-hydroxy-cinnamic acid (sinapinic acid) to enhance ionization of the sample. One microliter of the sample containing 5-10 pmol of the purified protein was mixed with 1  $\mu$ l of the matrix (10 mg/ml) dissolved in 70% (v/v) aqueous acetonitrile containing 0.1% (v/v) trifluoroacetic acid. One microliter of this sample and matrix mixture was loaded on a sample slide, allowed to dry and irradiated by a short pulse of UV light from a laser. Protein samples usually generate a relatively simple spectra in this method, since protein-related ions produced are predominantly of charge states  $z=+1$   $[M+H]^+$  and  $z=+2$   $[M+2H]^{2+}$ . Cytochrome C from bovine heart (Sigma Chemical Co., St. Louis, MO) of molecular weight 12,230.9 was used for external calibration.

The molecular weight of lipidated rP6 in the sample used was determined to be 15,078. In addition to the expected  $[M+H]^+$  molecular ion, the  $[M+2H]^{2+}$  molecular ion of lipidated rP6 was also observed. The theoretical molecular weight of P6 containing a tripalmitoyl cysteine residue at its N-terminus is 15,024 and the predicted molecular weight of P6 unprocessed by signal peptidase II is 16,016.66, whereas the predicted molecular weight of unlipidated P6 cleaved by signal peptidase II is 14,234.66. Thus, these results are consistent with the expression of the lipidated form of rP6 by *E. coli*.

- 29 -

Example 8

Amino Acid Composition Analysis

5        A sample of lipidated rP6 for amino acid analysis was dried down in glass tubes, followed by hydrolysis using 100  $\mu$ l of 6 N HCl containing 5% phenol and 1% 2-mercaptoethanol under vacuum for 22 hours at 110°C. The samples were subsequently dried under vacuum, followed by resolubilization in the sample dilution buffer Na-S (Beckman Instruments, Inc., Fullerton, CA). The amino acid composition was determined on a Beckman model 6300 Amino Acid Analyzer (55) using a three step Na-citrate gradient according to manufacturer's instructions. Threonine and serine residues were not corrected for destruction. Since cysteine and tryptophan residues were not determined by the method used, the results were expressed as mol of residues per mol of lipidated rP6 based on the theoretical molecular weight of unlipidated rP6 minus cysteines, which equals 14,132.4 (lipidated rP6 does not contain Trp). The results are shown in Table 1 and represent the mean of duplicate determinations. The results are consistent with the signal sequence of the pal gene having been removed by *E. coli*.

- 30 -

Table 1  
Amino Acid Analysis of lipidated rP6

Amino acid	Experimental mol residues/mol	Theoretical Mature mol residues/mol	Theoretical Pro-peptide mol residues/mol
Asp + Asn	16.6	17	18
Thr	6.6	7	7
Ser	7.0	6	8
Glu + Gln	12.5	12	12
Pro	2.8	3	3
Gly	16.9	16	17
Ala	18.9	21	26
Val	10.5	10	13
Met	0.2	0	1
Ile	2.9	3	3
Leu	8.4	9	12
Tyr	10.1	11	11
Phe	3.1	3	4
His	3.1	2	2
Lys	6.6	7	9
Arg	6.5	6	6
Cys	ND	1	1
Trp	ND	0	0

ND = Not determined

5

Example 9Amino-Terminal Amino Acid Sequence Analysis

10

Amino-terminal protein sequence analysis was carried out using an Applied Biosystems Model 477A Protein/Peptide Sequencer equipped with an on-line Model 120A PTH Analyzer (Applied Biosystems, Foster

- 31 -

City, CA). After the cleavage of each successive amino-terminus, the anilinothiazolinone derivative formed was converted to the more stable phenylthiohydantion (PTH) derivative by treatment with 5 25% trifluoroacetic acid at 64°C for 20 minutes. The PTH derivatives were separated and identified on the PTH analyzer by reversed-phase HPLC using an Brownlee PTH C-18 column (particle size 5  $\mu$ m, 2.1 mm i.d. x 22 cm l.; Applied Biosystems) with a modified two solvent gradient system developed by the manufacturer (56).

When lipidated rP6 (400 pmoles) was subjected to amino-terminal amino acid sequence analysis, no sequence data could be obtained. This suggested that the primary (or a secondary) amino group of the amino-terminal amino acid was not available for the sequencing chemistry, i.e., the amino-terminal residue of LrP6 was blocked. In order to substantiate that the inability to generate sequence data was not due to any instrument malfunction, a control experiment was subsequently run in which a mixture of 400 pmoles of lipidated rP6 and 200 pmoles of beta-lactoglobulin was subjected to amino-terminal sequence analysis. A single sequence representing the amino-terminal sequence of beta-lactoglobulin was obtained, which confirmed that the amino-terminal residue of lipidated rP6 was essentially blocked.

Example 10

Immunogenicity of Lipidated rP6  
Compared to Non-lipidated rP6

The relative immunogenicity of the purified lipidated recombinant P6 and non-lipidated recombinant P6 (28) were compared in Swiss-Webster mice. Each five 35  $\mu$ g dose of each protein was mixed with 100  $\mu$ g AlPO<sub>4</sub> and

- 32 -

50  $\mu$ g 3-O-deacylated monophosphoryl lipid A (MPL<sup>TM</sup>) (Ribi Immunochemicals, Hamilton, MT) were used to immunize mice subcutaneously at weeks 0, 4, and 6. Blood samples were taken at weeks 0, 4, 6, and 8.

5 Other groups of mice were immunized with mixtures of either non-lipidated rP6 or lipidated rP6 and the UspA2 protein of *Moraxella catarrhalis* (49), a causative agent of bacterial otitis media, and recombinant lipidated rP4 (50). These mixtures were also adjuvanted with AlPO<sub>4</sub> and MPL<sup>TM</sup> as above.

10 Antisera obtained from the mice were analyzed by ELISA for antibodies against either the P6, P4, or UspA2 proteins. ELISA titers were determined (22,28) for either pooled sera or individual animals and then the geometric mean titer (GMT) derived. The results are shown in Tables 2 and 3.

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000

- 33 -

**Table 2**  
**Anti-P6 ELISA Titers**

Immunogen	Anti-P6 ELISA Titer:		
	Week 0	Week 6	Week 8
5 µg rP6 (non-lipidated),	GMT	1,369	17,686
	Pool	<50	40,715
5 µg rP6 (lipidated)	GMT	341,987	780,179
	Pool	<50	706,826
5 µg each rP6 (non-lipidated), rP4, UspA	GMT	425	15,015
	Pool	<50	692
5 µg each rP6 (lipidated), rP4, UspA	GMT	251,731	1,052,527
	Pool	<50	739,896
			1,268,527

- 34 -

Table 3  
Anti-P4 and UspA2 ELISA Titers

Immunogen		Anti-P4 ELISA Titer:		Anti-UspA2 ELISA Titer:	
		Week 0	Week 4	Week 0	Week 4
5 µg each rP6 (non-lipidated), rP4, UspA	GMT		84,677		143,285
	Pool	<50	189,980	<50	247,003
5 µg each rP6 (lipidated), rP4, UspA	GMT		136,412		257,751
	Pool	<50	197,361	<50	335,548

The lipidated rP6 is at least one log more immunogenic than the non-lipidated rP6 when administered alone with MPL™ and AlPO<sub>4</sub> adjuvants. When combined with rP4 and UspA2, no antigenic competition was observed. In fact, the response to the lipidated rP6 was increased to approximately 1.5 logs greater than the response to the non-lipidated rP6.

Analysis of the immune response to the UspA2 and rP4 antigens shows that the addition of the lipidated rP6 did not alter the immune response to these antigens as compared to addition of the non-lipidated rP6. Neither antigen had any effect on the normal immune response seen when lipidated rP4 and UspA2 were mixed together. This demonstrated the compatibility of these antigens.

10019164 122001A  
5  
10  
10

15

20

25

- 35 -

Example 11

Bactericidal Activity of Mouse Antisera

5 Biologic activity of the antisera directed against the lipidated rP6 and the lipidated rP6/rP4 mixtures was demonstrated using an in vitro bactericidal assay. This assay was performed as previously described (22,28) using nontypable *H. influenzae* strain P861454 as the target. The results are shown in Table 4:

Table 4  
In Vitro Bactericidal Activity  
Of Antisera From Tables 2 and 3

Immunogen:	Week 6 Sera		Week 8 Sera	
	BC	Times (X)	BC	Times (X)
	Titer	Background	Titer	Background
rP6	3,200	8X	12,800	16X
L-rP6	3,200	4X	12,800	16X
rP6, rP4, UspA2	3,200	4X	6,400	8X
L-rP6, rP4, UspA2	3,200	4X	12,800	16X

20 The results demonstrated that the lipidated rP6 elicited biologically active antibodies in this assay. While the absolute titers did not differ between the lipidated and non-lipidated antisera, this may be due to the antisera being maximally bactericidal in this assay system, especially since the preimmune

- 36 -

sera demonstrated a high degree of nonspecific killing with the complement source used in this assay. The 5 lipidated rP6/rP4 mixture also elicited bactericidal antibodies at titers equivalent to those obtained with the non-lipidated rP6/rP4 mixture. It was not possible to distinguish between the bactericidal activity of the anti-rP4 antibodies and the anti-rP6 antibodies in this assay, but it is clear that the mixture of the *Haemophilus* antigens elicited highly bactericidal antisera against nontypable *H. influenzae*.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
3310  
3311  
3312  
3313  
3314  
3315  
3316  
3317  
3318  
3319  
3320  
3321  
3322  
3323  
3324  
3325  
3326  
3327  
3328  
3329  
3330  
3331  
3332  
3333  
3334  
3335  
3336  
3337  
3338  
3339  
3340  
3341  
3342  
3343  
3344  
3345  
3346  
3347  
3348  
3349  
3350  
3351  
3352  
3353  
3354  
3355  
3356  
3357  
3358  
3359  
3360  
3361  
3362  
3363  
3364  
3365  
3366  
3367  
3368  
3369  
33610  
33611  
33612  
33613  
33614  
33615  
33616  
33617  
33618  
33619  
33620  
33621  
33622  
33623  
33624  
33625  
33626  
33627  
33628  
33629  
33630  
33631  
33632  
33633  
33634  
33635  
33636  
33637  
33638  
33639  
33640  
33641  
33642  
33643  
33644  
33645  
33646  
33647  
33648  
33649  
33650  
33651  
33652  
33653  
33654  
33655  
33656  
33657  
33658  
33659  
33660  
33661  
33662  
33663  
33664  
33665  
33666  
33667  
33668  
33669  
336610  
336611  
336612  
336613  
336614  
336615  
336616  
336617  
336618  
336619  
336620  
336621  
336622  
336623  
336624  
336625  
336626  
336627  
336628  
336629  
336630  
336631  
336632  
336633  
336634  
336635  
336636  
336637  
336638  
336639  
336640  
336641  
336642  
336643  
336644  
336645  
336646  
336647  
336648  
336649  
336650  
336651  
336652  
336653  
336654  
336655  
336656  
336657  
336658  
336659  
336660  
336661  
336662  
336663  
336664  
336665  
336666  
336667  
336668  
336669  
3366610  
3366611  
3366612  
3366613  
3366614  
3366615  
3366616  
3366617  
3366618  
3366619  
3366620  
3366621  
3366622  
3366623  
3366624  
3366625  
3366626  
3366627  
3366628  
3366629  
3366630  
3366631  
3366632  
3366633  
3366634  
3366635  
3366636  
3366637  
3366638  
3366639  
3366640  
3366641  
3366642  
3366643  
3366644  
3366645  
3366646  
3366647  
3366648  
3366649  
3366650  
3366651  
3366652  
3366653  
3366654  
3366655  
3366656  
3366657  
3366658  
3366659  
3366660  
3366661  
3366662  
3366663  
3366664  
3366665  
3366666  
3366667  
3366668  
3366669  
33666610  
33666611  
33666612  
33666613  
33666614  
33666615  
33666616  
33666617  
33666618  
33666619  
33666620  
33666621  
33666622  
33666623  
33666624  
33666625  
33666626  
33666627  
33666628  
33666629  
33666630  
33666631  
33666632  
33666633  
33666634  
33666635  
33666636  
33666637  
33666638  
33666639  
33666640  
33666641  
33666642  
33666643  
33666644  
33666645  
33666646  
33666647  
33666648  
33666649  
33666650  
33666651  
33666652  
33666653  
33666654  
33666655  
33666656  
33666657  
33666658  
33666659  
33666660  
33666661  
33666662  
33666663  
33666664  
33666665  
33666666  
33666667  
33666668  
33666669  
336666610  
336666611  
336666612  
336666613  
336666614  
336666615  
336666616  
336666617  
336666618  
336666619  
336666620  
336666621  
336666622  
336666623  
336666624  
336666625  
336666626  
336666627  
336666628  
336666629  
336666630  
336666631  
336666632  
336666633  
336666634  
336666635  
336666636  
336666637  
336666638  
336666639  
336666640  
336666641  
336666642  
336666643  
336666644  
336666645  
336666646  
336666647  
336666648  
336666649  
336666650  
336666651  
336666652  
336666653  
336666654  
336666655  
336666656  
336666657  
336666658  
336666659  
336666660  
336666661  
336666662  
336666663  
336666664  
336666665  
336666666  
336666667  
336666668  
336666669  
3366666610  
3366666611  
3366666612  
3366666613  
3366666614  
3366666615  
3366666616  
3366666617  
3366666618  
3366666619  
3366666620  
3366666621  
3366666622  
3366666623  
3366666624  
3366666625  
3366666626  
3366666627  
3366666628  
3366666629  
3366666630  
3366666631  
3366666632  
3366666633  
3366666634  
3366666635  
3366666636  
3366666637  
3366666638  
3366666639  
3366666640  
3366666641  
3366666642  
3366666643  
3366666644  
3366666645  
3366666646  
3366666647  
3366666648  
3366666649  
3366666650  
3366666651  
3366666652  
3366666653  
3366666654  
3366666655  
3366666656  
3366666657  
3366666658  
3366666659  
3366666660  
3366666661  
3366666662  
3366666663  
3366666664  
3366666665  
3366666666  
3366666667  
3366666668  
3366666669  
33666666610  
33666666611  
33666666612  
33666666613  
33666666614  
33666666615  
33666666616  
33666666617  
33666666618  
33666666619  
33666666620  
33666666621  
33666666622  
33666666623  
33666666624  
33666666625  
33666666626  
33666666627  
33666666628  
33666666629  
33666666630  
33666666631  
33666666632  
33666666633  
33666666634  
33666666635  
33666666636  
33666666637  
33666666638  
33666666639  
33666666640  
33666666641  
33666666642  
33666666643  
33666666644  
33666666645  
33666666646  
33666666647  
33666666648  
33666666649  
33666666650  
33666666651  
33666666652  
33666666653  
33666666654  
33666666655  
33666666656  
33666666657  
33666666658  
33666666659  
33666666660  
33666666661  
33666666662  
33666666663  
33666666664  
33666666665  
33666666666  
33666666667  
33666666668  
33666666669  
336666666610  
336666666611  
336666666612  
336666666613  
336666666614  
336666666615  
336666666616  
336666666617  
336666666618  
336666666619  
336666666620  
336666666621  
336666666622  
336666666623  
336666666624  
336666666625  
336666666626  
336666666627  
336666666628  
336666666629  
336666666630  
336666666631  
336666666632  
336666666633  
336666666634  
336666666635  
336666666636  
336666666637  
336666666638  
336666666639  
336666666640  
336666666641  
336666666642  
336666666643  
336666666644  
336666666645  
336666666646  
336666666647  
336666666648  
336666666649  
336666666650  
336666666651  
336666666652  
336666666653  
336666666654  
336666666655  
336666666656  
336666666657  
336666666658  
336666666659  
336666666660  
336666666661  
336666666662  
336666666663  
336666666664  
336666666665  
336666666666  
336666666667  
336666666668  
336666666669  
3366666666610  
3366666666611  
3366666666612  
3366666666613  
3366666666614  
3366666666615  
3366666666616  
3366666666617  
3366666666618  
3366666666619  
3366666666620  
3366666666621  
3366666666622  
3366666666623  
3366666666624  
3366666666625  
3366666666626  
3366666666627  
3366666666628  
3366666666629  
3366666666630  
3366666666631  
3366666666632  
3366666666633  
3366666666634  
3366666666635  
3366666666636  
3366666666637  
3366666666638  
3366666666639  
3366666666640  
3366666666641  
3366666666642  
3366666666643  
3366666666644  
3366666666645  
3366666666646  
3366666666647  
3366666666648  
3366666666649  
3366666666650  
3366666666651  
3366666666652  
3366666666653  
3366666666654  
3366666666655  
3366666666656  
3366666666657  
3366666666658  
3366666666659  
3366666666660  
3366666666661  
3366666666662  
3366666666663  
3366666666664  
3366666666665  
3366666666666  
3366666666667  
3366666666668  
3366666666669  
33666666666610  
33666666666611  
33666666666612  
33666666666613  
33666666666614  
33666666666615  
33666666666616  
33666666666617  
33666666666618  
33666666666619  
33666666666620  
33666666666621  
33666666666622  
33666666666623  
33666666666624  
33666666666625  
33666666666626  
33666666666627  
33666666666628  
33666666666629  
33666666666630  
33666666666631  
33666666666632  
33666666666633  
33666666666634  
33666666666635  
33666666666636  
33666666666637  
33666666666638  
33666666666639  
33666666666640  
33666666666641  
33666666666642  
33666666666643  
33666666666644  
33666666666645  
33666666666646  
33666666666647  
33666666666648  
33666666666649  
33666666666650  
33666666666651  
33666666666652  
33666666666653  
33666666666654  
33666666666655  
33666666666656  
33666666666657  
33666666666658  
33666666666659  
33666666666660  
33666666666661  
33666666666662  
33666666666663  
33666666666664  
33666666666665  
33666666666666  
33666666666667  
33666666666668  
33666666666669  
336666666666610  
336666666666611  
336666666666612  
336666666666613  
336666666666614  
336666666666615  
336666666666616  
336666666666617  
336666666666618  
336666666666619  
336666666666620  
336666666666621  
336666666666622  
336666666666623  
336666666666624  
336666666666625  
336666666666626  
336666666666627  
336666666666628  
336666666666629  
336666666666630  
336666666666631  
336666666666632  
336666666666633  
336666666666634  
336666666666635  
336666666666636  
336666666666637  
336666666666638  
336666666666639  
336666666666640  
336666666666641  
336666666666642  
336666666666643  
336666666666644  
336666666666645  
336666666666646  
336666666666647  
336666666666648  
336666666666649  
336666666666650  
336666666666651  
336666666666652  
336666666666653  
336666666666654  
336666666666655  
336666666666656  
336666666666657  
336666666666658  
336666666666659  
336666666666660  
336666666666661  
336666666666662  
336666666666663  
336666666666664  
336666666666665  
336666666666666  
336666666666667  
336666666666668  
336666666666669  
3366666666666610  
3366666666666611  
3366666666666612  
3366666666666613  
3366666666666614  
3366666666666615  
3366666666666616  
3366666666666617  
3366666666666618  
3366666666666619  
3366666666666620  
3366666666666621  
3366666666666622  
3366666666666623  
3366666666666624  
3366666666666625  
3366666666666626  
3366666666666627  
3366666666666628  
3366666666666629  
3366666666666630  
3366666666666631  
3366666666666632  
3366666666666633  
3366666666666634  
3366666666666635  
3366666666666636  
3366666666666637  
3366666666666638  
3366666666666639  
3366666666666640  
3366666666666641  
3366666666666642  
3366666666666643  
3366666666666644  
3366666666666645  
3366666666666646  
3366666666666647  
3366666666666648  
3366666666666649  
3366666666666650  
3366666666666651  
3366666666666652  
3366666666666653  
3366666666666654  
3366666666666655  
3366666666666656  
3366666666666657  
3366666666666658  
3366666666666659  
3366666666666660  
3366666666666661  
3366666666666662  
3366666666666663  
3366666666666664  
3366666666666665  
3366666666666666  
3366666666666667  
3366666666666668  
3366666666666669  
33666666666666610  
33666666666666611  
33666666666666612  
33666666666666613  
33666666666666614  
33666666666666615  
33666666666666616  
33666666666666617  
33666666666

- 37 -

Bibliography

1. Ludwig, B., et al., Infect. Immun., 59, 2515-2521 (1991).
2. Lazzaroni, J.C., et al., Mol. Microbiol., 6, 735-742 (1992).
3. Spinola, S.M., et al., Infect. Immun., 64, 1950-1955 (1996).
4. Burnens, A., et al., J. Clin. Microbiol., 33, 2826-2832 (1995).
5. Rodriguez-Herva, J.J., et al., J. Bacteriol., 178, 1699-1706 (1996).
6. Tibor, A., et al., Infect. Immun., 62, 3633-3639 (1994).
7. Mizuno, T., J. Biochem. (Tokyo), 89, 1039-1049 (1981).
8. Frey, J., et al., Res. Microbiol., 147, 351-361 (1996).
9. Tomb, J.F., et al., Nature, 388, 539-547 (Aug. 7, 1997).
10. PCT International Application Number WO 99/27105.
11. PCT International Application Number WO 99/28475.
12. Fraser, D.W., et al., Am. J. Epidemiol., 100, 29-34 (1974).
13. Murphy, T.F., et al., J. Infect. Dis., 152, 1300-1307 (1985).
14. Bluestone, C.D., and Klein, J.O., Pediatric Otolaryngology, p. 356 (Bluestone and Stool, eds., W.B. Saunders Co. Philadelphia (1983)).
15. Musher, D.M., et al., Ann. Intern. Med., 99, 344-350 (1983).
16. Walker, R.J., Jr., et al., Ann. Rev. Infect. Dis., 5, 123-135 (1983).

17. Cherry J.D., and Dudley, J.P., Textbook of Pediatric Infectious Diseases, pages 103-105 (Feigin and Cherry eds., (W.B. Saunders & Co., Philadelphia, PA (1981)).

18. Munson, R., Jr., and Tolan, R.W., Jr., Infect. Immun., 57, 88-94 (1989).

19. van Alphen, L., et al., Infect. Immun., 59, 247-252 (1991).

20. Bernstein, J.M., et al., Otolaryngol. Head Neck Surg., 105, 406-410 (1991).

21. United States Patent Number 5,110,908.

22. Green, B.A., et al., Infect. Immun., 59, 3191-3198 (1991).

23. Green, B.A., et al., Infect. Immun., 55, 2878-2883 (1987).

24. Munson, R.S., Jr., and Granoff, D.M., Infect. Immun., 49, 544-549 (1985).

25. Murphy, T.F., et al., J. Clin. Invest., 78, 1020-1027 (1986).

26. Murphy, T.F., et al., Infect. Immun., 54, 774-777 (1986).

27. Murphy, T.F., et al., Pediatr. Infect. Dis. J., 8, S66-68 (1989).

28. Green, B.A., et al., Infect. Immun., 58, 3272-3278 (1990).

29. Yang, Y.P., et al., Vaccine, 15, 976-987 (1997).

30. Green, B.A., and Deich, R.A., Current Opinion in Therapeutic Patents, 1, 669-680 (1991).

31. Green, B.A., et al., Infect. Immun., 61, 1950-1957 (1993).

32. Akkoyunlu, M., et al., Infect Immun., 65, 5010-5016 (1997).

33. Zlotnick, G.W., et al., J. Biol. Chem., 263, 9790-9794 (1988).

- 39 -

34. Faden, H., et al., J. Infect. Dis., 160, 999-1004 (1989).

35. Faden, H.S., et al., "Antibody response to nontypable *Haemophilus influenzae*." in Proceedings of the Fourth International Symposium on Otitis Media with Effusion., p. 340-343. (Lim, Bluestone, Klein and Nelson, eds. Toronto, Ontario, Canada (1987)).

36. Kodama, H., et al., Acta Oto Laryngologica Supplement, 523, 153-4 (1996).

37. Lim, A., Jr., et al., Microbiology, 143, 1709-1716 (1997).

38. Guzman, L.-M., et al., J. Bacteriol., 177, 4121-4130 (1995).

39. Mertens, N., et al., Gene, 16, 9-15 (1995).

40. Mertens, N., Biotechnology (N.Y.), 13, 175-179 (1995).

41. Chandrashekharan, S., et al., Biol. Chem., 379, 579-582 (1998).

42. Reddy, P., et al., Nucleic Acids Res., 25, 10473-10488 (1989).

43. Sagawa, H., et al., Gene, 168, 37-41 (1996).

44. Waleh, N.S., Gene, 117, 7-14 (1992).

45. Skerra, A., Gene, 151, 131-5 (1994).

46. Haldimann, A., et al., J. Bacteriol., 180, 1277-1286 (1998).

47. Lutz, R., et al., Nucleic Acids Res., 25, 1203-1210 (1997).

48. Wulffing, C., Gene, 136, 199-203 (1993).

49. PCT International Application Number WO 98/28333.

50. United States Patent Number 5,601,831.

51. PCT International Application Number WO 00/18434.

- 40 -

52. Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
53. Laemmli, U.K., Nature (London), 227, 680-685 (1970).
54. Hillenkamp, F., and Karas, M., Meth. Enzymol., 193, 280-95 (1990).
55. Arrizon-Lopez, V., et al., "High-Performance Liquid Chromatography of Peptides and Proteins: Separation, Analysis, and Conformation." In p. 859-863. Hodges ed. (CRC Press. Boca Raton, Florida 1991).
56. Sengoku, Y., et al., "Protein Analysis Renaissance" (Applied Biosystems. Foster City, CA 1993).

- 41 -

What is claimed is:

1. A plasmid containing a tightly regulated promoter, wherein said promoter is operatively linked to an isolated and purified DNA sequence comprising a DNA sequence which encodes a peptidoglycan-associated lipoprotein (PAL) of gram-negative bacteria and wherein said DNA sequence, under the control of said promoter, is expressed in lipidated form.
2. The plasmid of Claim 1 wherein the PAL is the P6 protein of *Haemophilus influenzae* (*H. influenzae*).
3. The plasmid of Claim 2 wherein the promoter is an arabinose inducible promoter or a T7 promoter.
4. The plasmid of Claim 3 wherein the promoter is an arabinose inducible promoter.
5. The plasmid of Claim 4 wherein the plasmid is designated pPX4020.
6. The plasmid of Claim 3 wherein the promoter is a T7 promoter.
7. The plasmid of Claim 6 wherein the plasmid is designated pPX4019.
8. A bacterial host cell transformed, transduced or transfected with the plasmid of Claim 1.
9. A method of producing a recombinant lipidated PAL, which comprises transforming, transducing or transfecting a bacterial host cell with the plasmid of Claim 1 and culturing the host cell under conditions which permit the expression of said lipidated recombinant PAL by the host cell.
10. The method of Claim 9 wherein the PAL is the P6 protein of *H. influenzae*.
11. An antigenic composition comprising lipidated recombinant PAL, wherein said antigenic

- 42 -

composition elicits a protective immune response in a mammalian host.

12. The antigenic composition of Claim 11 wherein the PAL is the P6 protein of *H. influenzae*.


13. The antigenic composition of Claim 11 which further comprises one or more of a diluent or carrier.

14. The antigenic composition of Claim 11 which further comprises at least one adjuvant.

15. The antigenic composition of Claim 14 wherein the adjuvant is selected from the group consisting of at least one of aluminum hydroxide, aluminum phosphate, Stimulon™ QS-21, 3-O-deacylated monophosphoryl lipid A, IL-12, the heat-labile toxin of *E. coli*, and wild-type or mutant cholera toxin.

16. A method of immunizing against a gram-negative bacterium which comprises administering to a mammalian host an immunogenic amount of the antigenic composition of Claim 11.

17. The method of Claim 16 wherein the gram-negative bacterium is *H. influenzae* and the antigenic composition includes lipidated rP6.



**FIG. 1**  
**SUBSTITUTE SHEET (RULE 26)**

2/3




FIG.2A




FIG.2B

3/3




FIG.3

**COMBINED DECLARATION AND POWER OF ATTORNEY**  
(Original, Design, Supplemental, Divisional, Continuation,CIP)

As the below named inventor, I hereby declare that:

**INVENTORSHIP IDENTIFICATION**

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

Production of the Lipidated Form of the Peptidoglycan-Associated Lipoproteins of Gram-Negative Bacteria

**SPECIFICATION IDENTIFICATION**

the specification of which: (complete (a), (b), or (c))

- (a)  was described and claimed in PCT International Application No. PCT/US00/17020 filed on June 20, 2000, which is now entering the U.S. National Stage.
- (b)  was filed on as
  - Serial Number
  - Express Mail No. , as Serial Number not yet known
- (c)  was described and claimed in PCT International Application No. filed on and as amended under PCT Article 19 on (if any).

**ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37 CFR 1.56(a).

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventors certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate of any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed.

(d)  No such applications have been filed.  
(e)  Such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. claimed priority, check item (e), enter the details below and make the priority claim.

Earliest Foreign Application(s), if any, filed within 12 months (6 months for Design) prior to this U.S. Application

Country	Application No.	Date of Filing (Day, Month, Year)	Priority Claimed 35 USC 119

All Foreign Application(s), if any, Filed More Than 12 Months  
(6 Months for Design) Prior to This U.S. Application)

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
**(35 U.S.C. § 119(E))**

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

**PROVISIONAL APPLICATION NUMBER**

**FILING DATE**

60/141,061

June 25, 1999

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)**  
**(UNDER 35 U.S.C. 120)**

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT International filing date of this application.

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS  
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 USC 120**

<b>U.S. Applications</b>		<b>Status (Check One)</b>		
<b>U.S. Applications</b>	<b>U.S. Filing Date</b>	<b>Patented</b>	<b>Pending</b>	<b>Abandoned</b>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

<b>PCT Applications Designating U.S.</b>		
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NO. ASSIGNED (if any)
PCT/US00/17020	6/20/00	

**POWER OF ATTORNEY**

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Customer Number: 25291

Bar Code:



Attached as part of this declaration and power of attorney is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s).

**SEND CORRESPONDENCE TO:**

Customer Number: 25291

Bar Code:



**DIRECT ALL TELEPHONE CALLS TO:**

Name: Alan M. Gordon

Tel. No. (845) 602-4636

DECLARATION

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Full name of SOLE OR FIRST INVENTOR: Benjamin J. Metcalf

Inventor's Signature Benjamin J. Metcalf Date 11/28/01

Country of Citizenship: **United States of America**

Residence : **15 Rensselaer Drive, Rochester, New York 14618 NY**

Post Office Address: **15 Rensselaer Drive, Rochester, New York 14618**

Full name of SECOND JOINT INVENTOR:

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Country of Citizenship:

Residence :

Post Office Address:

Full name of THIRD JOINT INVENTOR:

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Country of Citizenship:

Residence :

Post Office Address:

Full name of FOURTH JOINT INVENTOR:

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Country of Citizenship:

Residence :

Post Office Address: